Both in Pharmaceuticals
Arrowhead Research vs Spyre Therapeutics
Over the past year ARWR returned +51.2% and SYRE returned +306.1%; their daily moves had a correlation of 0.30.
ARWR +51.2% SYRE +306.1%Growth of $1, one year, split-adjusted
| Metric | ARWR | SYRE |
|---|---|---|
| Price | $59.90 | $96.56 |
| Market cap | $8.46B | $9.02B |
| Today | −0.98% | −2.43% |
| 1 month | −7.5% | +7.4% |
| 6 months | −19.9% | +39.1% |
| Year to date | −9.8% | +194.7% |
| 1 year | +48.7% | +305.2% |
| Revenue growth (YoY) | +171.0% | — |
| Gross margin | 100.0% | — |
| Net margin | −258.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 12.6× | — |
| Net cash | $737.9M | $1.15B |
| Dividend yield | — | — |
| Volatility (60d) | 45.6% | 58.7% |
| Short % of float | 8.1% | 15.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).